Novo Nordisk Current Ratio 2006-2019 | NVO

Current and historical current ratio for Novo Nordisk (NVO) from 2006 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Novo Nordisk current ratio for the three months ending March 31, 2019 was 0.96.
Novo Nordisk Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $8.03B $8.33B 0.96
2018-12-31 $9.03B $8.28B 1.09
2018-09-30 $8.45B $7.71B 1.10
2018-06-30 $9.21B $7.87B 1.17
2018-03-31 $8.24B $7.29B 1.13
2017-12-31 $9.13B $7.15B 1.28
2017-09-30 $9.02B $7.13B 1.27
2017-06-30 $8.72B $6.48B 1.35
2017-03-31 $7.98B $7.01B 1.14
2016-12-31 $8.88B $7.05B 1.26
2016-09-30 $7.74B $6.24B 1.24
2016-06-30 $7.99B $6.31B 1.27
2016-03-31 $6.86B $6.08B 1.13
2015-12-31 $8.21B $6.08B 1.35
2015-09-30 $7.68B $5.74B 1.34
2015-06-30 $7.02B $5.72B 1.23
2015-03-31 $6.59B $6.37B 1.04
2014-12-31 $8.25B $6.01B 1.37
2014-09-30 $7.33B $5.35B 1.37
2014-06-30 $6.29B $4.37B 1.44
2014-03-31 $6.34B $4.85B 1.31
2013-12-31 $7.49B $4.31B 1.74
2013-09-30 $7.27B $4.56B 1.59
2013-06-30 $6.40B $4.45B 1.44
2013-03-31 $6.34B $4.54B 1.40
2012-12-31 $6.94B $3.74B 1.86
2012-09-30 $6.87B $4.41B 1.56
2012-06-30 $6.21B $4.12B 1.51
2012-03-31 $6.41B $3.88B 1.65
2011-12-31 $7.40B $3.88B 1.91
2011-09-30 $7.37B $3.87B 1.91
2011-06-30 $7.31B $3.59B 2.04
2011-03-31 $6.51B $3.35B 1.94
2010-12-31 $6.65B $3.29B 2.02
2010-09-30 $5.87B $2.93B 2.00
2010-06-30 $5.78B $3.13B 1.85
2010-03-31 $5.84B $2.89B 2.02
2009-12-31 $6.12B $2.51B 2.44
2009-09-30 $5.95B $2.48B 2.40
2009-06-30 $5.44B $2.28B 2.38
2009-03-31 $5.02B $2.48B 2.03
2008-12-31 $5.73B $2.55B 2.24
2008-09-30 $5.48B $2.49B 2.20
2008-06-30 $5.51B $2.32B 2.38
2008-03-31 $4.98B $2.33B 2.13
2007-12-31 $4.47B $1.96B 2.28
2007-09-30 $4.30B $1.99B 2.16
2007-06-30 $4.15B $1.91B 2.17
2007-03-31 $3.68B $1.88B 1.97
2006-12-31 $3.50B $1.71B 2.05
2006-09-30 $3.51B $1.96B 1.79
2006-06-30 $3.41B $1.72B 1.99
2006-03-31 $3.04B $1.69B 1.80
2005-12-31 $3.27B $1.77B 1.85
2005-09-30 $2.94B $1.51B 1.95
2005-06-30 $2.72B $1.45B 1.87
2005-03-31 $2.84B $1.29B 2.19
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $116.141B $17.724B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $370.562B 16.80
Pfizer (PFE) United States $248.056B 13.53
Merck (MRK) United States $214.347B 17.63
Novartis AG (NVS) Switzerland $190.321B 16.44
AbbVie (ABBV) United States $119.568B 9.89
Eli Lilly (LLY) United States $113.179B 21.00
Sanofi (SNY) France $103.283B 12.67
GlaxoSmithKline (GSK) United Kingdom $97.711B 12.39
AstraZeneca (AZN) United Kingdom $95.946B 11.04
Bristol-Myers Squibb (BMY) United States $77.582B 11.46